The hybridoma technique for producing monoclonal antibodies, developed by Drs. Kohler and Millstein in 1975, revolutionized the field of tumor immunology. It is now clear that there are antigens associated with or restricted to human neoplasms that have biologic significance. Monoclonal antibodies have already been demonstrated to have great immunodiagnostic value and it is anticipated that they will become a component of our therapeutic armamentarium. Most investigators in the field, however, feel that the true potential of monoclonal antibodies in cancer therapy remains to be determined. Clearly the most encouraging results have been witnessed in the treatment of hematologic malignancies. This volume of CANCER TREATMENT AND RESEARCH explores the current state of the art of immunoconjugate therapy of hematologic malignancies. Immunoconjugate Therapy of Hematologic Malignancies provides an update of a rapidly advancing field. The preliminary experience of a number of investigators suggests a role for targeted therapy in the treatment of hematologic malignancies. At the present time, immunoconjugates have, in most instances, been reserved for patients with advanced refractory disease. However, it is anticipated in the future that these reagents will be utilized as a complement to traditional therapy or as post-remission consolidation in patients with minimal residual disease. The obstacles have been defined; solutions will require further research and creative imagination.

Presents timely and authoritative information on the development of precision cancer therapies as applied to hematologic malignancies The Precision Cancer Therapies series focuses on how to understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners of this science. Precision Cancer Therapies, Volume Two, focuses on sophisticated immunotherapies targeting cancers affecting the blood, bone marrow, and lymph nodes. Edited and authored by the foremost authorities in the field, this comprehensive reference text covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T). Divided into nine sections, Volume Two includes an overview of the history of immunotherapy development in cancer, as well as a concluding section addressing the mechanistic basis and role of immunomodulatory drugs, analytical tools to quantitate immune-mediated effects, and other topics in immunotherapy. Chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. This book also: Delivers a definitive, state-of-the-art review of the relevant biology and its importance in the broader context of cancer biology Focuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanisms Covers FDA-approved drugs and their indications, as well as drugs currently in development Provides information on monotherapy and combination therapy, summary tables of trials, and discussion of toxicity and efficacy Includes boxed sections highlighting major unique points about the information in the chapter Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, From Concept to Practice is an indispensable resource for medical, scientific, and allied medical professionals, advanced students, and interested general readers with background knowledge in the subject.

There is no field of medicine in which advances in therapy have been so closely linked to a better understanding of molecular medicine than in the area of hematologic malignancies. Diagnostic and Therapeutic Advances in Hematologic Malignancies will provide practitioners and academic clinicians with a better understanding of the constant evolving concepts in this area.

The book Advances in Hematologic Malignancies presents new knowledge of cellular disease processes, molecular pathology, and cytogenetic, epigenetic, and genomic changes that have influenced the current outlook toward hematological malignancies. This book provides a unique, practical, and concise guide that is focused on the must-know points of diagnosis, prognosis, therapeutic management, and cutting edge clinical trial opportunities for each hematologic malignancy. Advances in Hematologic Malignancies is designed and organized as an essential reference source for the hematologist, hematologic oncologist, hematopathologist, and trainee.

Radiation Medicine Rounds is a trinary hard cover periodical designed to provide an up-to- date review of a dedicated radiation medicine topic of interest to clinicians and scientists who are involved in the care of patients receiving radiotherapy. It is intended to serve as both a reference and instructional tool for students, housestaff, fellows, practicing clinicians, medical physicists, cancer biologists, radiobiologists, and interdisciplinary colleagues throughout the oncology spectrum. This issue of Radiation Medicine Rounds discusses the more salient topics surrounding the role of radiation therapy for hematologic malignancies. There are literally dozens of distinct lymphoma subtypes, each with its own unique molecular and clinical features. Although systemic cytotoxic and targeted therapies have improved dramatically, radiation therapy remains an important modality for optimal clinical outcomes. With contributions from nationally recognized experts, Hematologic Malignancies offers an overview of the full spectrum of therapy for hematologic malignancies ranging from lymphoma and leukemia to plasma cell dyscrasias. Recent advances in radiotherapy for hematologic malignancies allow for maintenance of excellent local control with improvements in toxicity achieved through reductions in field sizes, in dose delivered, and increasingly conformal delivery techniques. Hematologic Malignancies provides the practitioner with a current overview of best practices, recent research, and future directions in the management of these complex cancers.

Hematologic malignancies were the first human cancers to be studied in depth at the molecular level, and recent years have seen important advances in treatment. This comprehensive reference book covers the full range of hematologic malignancies, including all subtypes of leukemias, lymphomas, and plasma cell dyscrasias. Authored by internationally known experts, each chapter emphasizes diagnostic work-up, staging, and therapeutic approaches. Up-to-date hematopathology, treatment, and outcomes data are presented in a way which is directly applicable to patient care. Highly illustrated with color images, graphs, flowcharts and treatment algorithms, the book is perfect for quick clinical reference as well as providing detailed reference lists for further study. With its authoritative and practical focus and visually stimulating presentation, this is a key text for hematology and oncology fellows, physicians, oncology nurses, physician assistants and other healthcare workers in the field of oncology.